Recordati (REC.MI)

Executive Summary

Recordati is a century-old Italian pharmaceutical company with a market cap of ~€10.2B, focused on small molecules for rare and specialty diseases. Its flagship product, Isturisa (osilodrostat), is approved for Cushing's syndrome and is being investigated for mild autonomous cortisol secretion (MACS) in a Phase 2/3 trial. The company also has a diverse pipeline including siltuximab/erenumab for schwannomatosis (Phase 2) and carglumic acid for hyperammonemia (Phase 2/3). Recordati generates robust cash flows from its commercial portfolio and maintains a strong balance sheet, enabling continued investment in R&D and business development. The company's strategy centers on in-licensing and acquiring niche products, which has historically delivered steady growth. However, near-term pipeline catalysts are limited, with most ongoing trials having distant primary completion dates.

Upcoming Catalysts (preview)

• Q4 2027Phase 2 data readout for siltuximab/erenumab in schwannomatosis30% success
• TBDOsilodrostat label expansion for mild autonomous cortisol secretion (MACS)40% success